Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis

  • Richard N Greenberg,
  • Maria Yadira Hurley,
  • Dinh V. Dinh,
  • Serena Mraz,
  • Javier Gomez Vera,
  • Dorothea von Bredow,
  • Alfred von Krempelhuber,
  • Siegfried Roesch,
  • Garth Virgin,
  • Nathaly Arndtz-Wiedemann,
  • Thomas Peter Meyer,
  • Darja Schmidt,
  • Richard Nichols,
  • Philip Young,
  • Paul Chaplin

Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis

  • Richard N Greenberg, 
  • Maria Yadira Hurley, 
  • Dinh V. Dinh, 
  • Serena Mraz, 
  • Javier Gomez Vera, 
  • Dorothea von Bredow, 
  • Alfred von Krempelhuber, 
  • Siegfried Roesch, 
  • Garth Virgin, 
  • Nathaly Arndtz-Wiedemann
PLOS
x

The second author’s name is spelled incorrectly. The correct name is: Maria Yadira Hurley. The correct citation is: Greenberg RN, Hurley MY, Dinh DV, Mraz S, Vera JG, von Bredow D, et al. (2015) A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis. PLoS ONE 10(10): e0138348. doi:10.1371/journal.pone.0138348

Reference

  1. 1. Greenberg RN, Hurley Y, Dinh DV, Mraz S, Vera JG, von Bredow D, et al. (2015) A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis. PLoS ONE 10(10): e0138348. pmid:26439129